Publication

DNMT3A mutations in acute myeloid leukemia.

Authors not recorded

N Engl J Med2010PMID 21067377PMC3201818stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (7)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 7

cancerAcute Myeloid Leukemiacivic_curation1.00
geneDNMT3Acivic_curation1.00
geneFLT3civic_curation1.00
geneNPM1civic_curation1.00
variantDNMT3A R882civic_curation1.00
variantFLT3 ITDcivic_curation1.00
variantNPM1 W288FScivic_curation1.00

Curated evidence

Evidence citing this paper (9)

civicCuratedShowing 1–9 of 9 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
DNMT3A R8825
(prognostic)	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	4	accepted	EID25 De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation. PMID 21067377 · Ley et al., 2010 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	5	accepted	EID62 AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation. PMID 21067377 · Ley et al., 2010 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	5	accepted	EID64 In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation. PMID 21067377 · Ley et al., 2010 · Open in CIViC	civic
(diagnostic)	Acute Myeloid LeukemiaCURATED_BROADER	Diagnostic	B	Supports Positive	5	accepted	EID112 DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes. PMID 21067377 · Ley et al., 2010 · Open in CIViC	civic
(prognostic)	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Does Not Support Better Outcome	2	accepted	EID113 DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype) and not favorable risk cytogenetic abnormalities (PML::RARA, RUNX1::RUNX1T1, … (full text at CIViC) PMID 21067377 · Ley et al., 2010 · Open in CIViC	civic
DNMT3A R882P1
(diagnostic)	Acute Myeloid LeukemiaCURATED_BROADER	Diagnostic	B	Supports Positive	5	submitted	EID7228 DNMT3A R882P somatic mutation, together with R882H, R882C and R882S were identified from Acute Myeloid Leukemia (AML) patients. And R882P, R882H and R882C were revealed as significant hotspot mutation… (full text at CIViC) PMID 21067377 · Ley et al., 2010 · Open in CIViC	civic
FLT3 ITD1
(prognostic)	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Supports Poor Outcome	5	accepted	EID69 In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation. PMID 21067377 · Ley et al., 2010 · Open in CIViC	civic
NPM1 W288FS2
(prognostic)	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Does Not Support Better Outcome	2	accepted	EID109 No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients). PMID 21067377 · Ley et al., 2010 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Prognostic	B	Does Not Support Better Outcome	2	rejected	EID121 NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype). PMID 21067377 · Ley et al., 2010 · Open in CIViC	civic